6 citations
,
October 2023 in “JAAD Case Reports” This document discusses two case reports of refractory dissecting cellulitis of the scalp (DCS), a rare and aggressive chronic inflammatory condition that primarily affects males and African Americans, leading to scarring alopecia and significant psychological distress. The study highlights the use of risankizumab, a medication typically used for psoriasis, as a treatment option for DCS. The cases demonstrate that risankizumab may be effective in managing symptoms and improving the quality of life for patients with this debilitating condition.
June 2023 in “British Journal of Dermatology” Baricitinib was effective and safe for severe hair loss treatment over 6 months.
June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
48 citations
,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
7 citations
,
October 2012 in “PubMed” Triamcinolone regrows hair better but relapses more than anthralin.
October 2025 in “Frontiers in Medicine” Ixekizumab has known and some unexpected side effects.
March 2019 in “Reactions Weekly” 6 citations
,
November 2018 in “Case reports in nephrology and dialysis” Rituximab may be an effective treatment for Cronkhite-Canada syndrome with kidney disease.
1 citations
,
November 2016 in “Congenital Anomalies” Get head MRI for babies with achondroplasia early, use free immunoglobulin light chains to detect certain neurodevelopmental disorders, and video calls work for speech therapy in patients with facial anomalies.
December 2025 in “Scientific Reports” Cedrol may help reduce liver fat and fat cell growth caused by corticosteroids.
June 2025 in “British Journal of Dermatology” JAK inhibitors help regrow hair in alopecia areata, but their long-term safety is still unclear.
January 2007 in “Yearbook of Dermatology and Dermatologic Surgery” Intramuscular triamcinolone and pulse therapy with oral predonine are effective for alopecia areata with manageable side effects, but better relapse prevention is needed.
June 2020 in “Annals of the Rheumatic Diseases” Patients need better information about the risks of long-term steroid use.
3 citations
,
February 2020 in “The journal of gene medicine” A mutation in the HR gene causes a rare form of irreversible hair loss in two Kashmiri families. Whole exome sequencing is effective for finding such mutations.
April 2023 in “Journal of the American Academy of Dermatology” Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
6 citations
,
September 2014 in “Cutaneous and ocular toxicology” Acitretin can cause eyebrow and eyelash hair loss.
3 citations
,
November 2020 in “Dermatologic Therapy” Start with 2.5 mg/mL triamcinolone acetonide for scalp alopecia areata and increase if needed.
Integrating ABI screening in clinics can improve patient care for those at risk of peripheral artery disease.
January 2018 in “Our Dermatology Online” Trichomycosis axillaris is a treatable bacterial infection of underarm hair.
2 citations
,
May 2024 in “International Journal of Medical Arts” Diphenylcyclopropenone (DPCP) is more effective than anthralin for treating resistant alopecia areata.
8 citations
,
May 2020 in “Arthritis research & therapy” DHT inhibition may increase spinal bone growth in ankylosing spondylitis.
20 citations
,
June 2019 in “Archives of dermatological research” Combining DPCP and anthralin helps regrow hair in some alopecia areata patients.
November 2022 in “Orphanet Journal of Rare Diseases” Long-term use of androgens can help manage Hereditary Angioedema (HAE) but may cause serious side effects, so alternative treatments with fewer side effects are being considered.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
July 2024 in “Reactions Weekly” February 2025 in “Skin Appendage Disorders” Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.
1 citations
,
November 2018 in “Therapeutic Delivery” New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
Cyproterone acetate is an effective treatment for women with acne, hair loss, and excessive hair growth.
9 citations
,
January 2015 in “Medical hypotheses” TCDD disrupts skin stem cells, causing skin issues like chloracne.